166 related articles for article (PubMed ID: 10423106)
1. Summary of randomized trials of angiotensin converting enzyme inhibitors.
Yusuf S; Lonn E; Bosch J; Gerstein H
Clin Exp Hypertens; 1999; 21(5-6):835-45. PubMed ID: 10423106
[TBL] [Abstract][Full Text] [Related]
2. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
Shah AD; Arora RR
Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
[TBL] [Abstract][Full Text] [Related]
3. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
4. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypertension in diabetes mellitus.
de La Sierra A; Ruilope LM
Curr Hypertens Rep; 2000 Jun; 2(3):335-42. PubMed ID: 10981168
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
7. Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function.
Lang CD; Arora RR; Saha SA; Molnar J
J Cardiometab Syndr; 2008; 3(1):45-52. PubMed ID: 18326970
[TBL] [Abstract][Full Text] [Related]
8. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
Feldt-Rasmussen BF
Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
[No Abstract] [Full Text] [Related]
9. Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
Doggrell SA
Expert Opin Pharmacother; 2002 Nov; 3(11):1543-56. PubMed ID: 12437489
[TBL] [Abstract][Full Text] [Related]
10. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
[TBL] [Abstract][Full Text] [Related]
12. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Saha SA; Molnar J; Arora RR
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
[TBL] [Abstract][Full Text] [Related]
13. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
14. Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.
Goa KL; Haria M; Wilde MI
Drugs; 1997 Jun; 53(6):1081-105. PubMed ID: 9179532
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers in patients with type 2 diabetes and retinopathy.
Shih CJ; Chen HT; Kuo SC; Li SY; Lai PH; Chen SC; Ou SM; Chen YT
CMAJ; 2016 May; 188(8):E148-E157. PubMed ID: 27001739
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
17. ACE inhibitors in heart failure: what more do we need to know?
Demers C; Mody A; Teo KK; McKelvie RS
Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
[TBL] [Abstract][Full Text] [Related]
18. Drug treatment for hypertensive patients in special situations: diabetes and hypertension.
Mogensen CE
Clin Exp Hypertens; 1999; 21(5-6):895-906. PubMed ID: 10423111
[TBL] [Abstract][Full Text] [Related]
19. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
[TBL] [Abstract][Full Text] [Related]
20. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement.
Hager WD; Davis BR; Riba A; Moye LA; Wun CC; Rouleau JL; Lamas GA; Pfeffer MA
Am Heart J; 1998 Mar; 135(3):406-13. PubMed ID: 9506325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
